Granted Patent B2

US 12,698,292 · App. 18/274,905 · Granted Aug 4, 2026

Inventors: Ao Li (Shanghai, CN); Yile Chen (Hangzhou, CN); Guoqing Cao (Hangzhou, CN)

Assignees: MINGHUI PHARMACEUTICAL (HANGZHOU) LIMITED; MINGHUI PHARMACEUTICAL (SHANGHAI) LIMITED

C07D491/22A61P35/00

Abstract

Claims (12)

1 . A compound of formula (I), or a pharmaceutically acceptable salt thereof:

wherein:

X is selected from the group consisting of H, OH, and NH 2 ;

Y is (CR 1 R 2 ) n ;

Z is chemical bond or C(O);

n is selected from 0, 1, 2, or 3;

and when n is 2 or 3, each CR 1 R 2 is the same or different;

R 1 and R 2 are independently selected from the group consisting of hydrogen, deuterium, halogen, C 1 -C 8 alkyl, C 1 -C 8 haloalkyl, C 1 -C 8 deuterated alkyl, C 1 -C 8 hydroxyalkyl, and C 3 -C 8 cycloalkyl;

or, R 1 and R 2 together with their attached carbon atoms form a C 3 -C 8 cycloalkyl;

and C 1 -C 8 alkyl is optionally substituted by substituents selected from the group consisting of C 6 -C 10 aryl, C 3 -C 6 cycloalkyl.

2 . The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound has a structure as shown in the following formula:

3 . A pharmaceutical composition comprising a compound of formula I according to claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents, or carriers.

Assignments (1)

Priority Claims (1)

Continuity (1)

References Cited (15)